Biographies

John P. Clancy, MD

Research Director, Division of Pulmonary Medicine

Professor, UC Department of Pediatrics

Phone: 513-636-6771

Email: john.clancy@cchmc.org

Show All

Specialties

Cystic fibrosis; airway cellular biology; CFTR regulation

Biography

John P. Clancy, MD, has served in several leadership roles at Univeristy of Alabama, Cincinnati Children's and within the international cystic fibrosis (CF) community. Some of his leadership roles include membership on the CFF Clinical Research Committee (2003 – present), the CFF-TDN Steering Committee (2002 – 2007), the CFF-TDN Translational Research Center Committee (2008 – present), DSMB membership for the Rare Lung Disease Consortium within the NIH Rare Disease Research Network (2005-2009, Chairman from 2010 – present)); organizing committee membership for the North American CF Conference (2003- present) and the European CF Society (2010), Co-chair of the CFFT Biomarkers Consortium (2010- present), member of the Promotion and Tenure Committee for the UAB Department of Pediatrics (2003 - 2010) and the UAB SOM (2007 – 2010, including committee Chair).

Dr. Clancy has been the primary or co-mentor of more than 20 fellows, graduate students and junior faculty. He has been the initial recipient of two endowed chairs, including the Raymond K. Lyrene Chair in Pediatric Pulmonary Medicine at the University of Alabama (2005), and the Tom Boat Chair in Cystic Fibrosis Clinical and Translational Research at Cincinnati Children's (2011).

Education and Training

MD: University of Iowa College of Medicine, Iowa City, IA.

Residency: University of Virginia, Charlottesville, VA.

Fellowship: University of Alabama at Birmingham, Birmingham, AL.

Publications

View PubMed Publications

Grants

Developing GI Outcome Measures for CFTR Modulator Trials in Young CF Patients. Principal Investigator. Feb 2010 - Jan 2012.

An Open-Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in Subjects with Cystic Fibrosis. Site Principal Investigator. Vertex Pharmaceuticals Incorporated. Jun 2011 - Jun 2012.

Randomized, Placebo-Controlled, Active-Controlled Multicenter Study to assess the Efficacy, Safety and Tolerability of Arikace® in Cystic Fibrosis with Chronic Infection Due to Pseudomonal aeruginosa. Principal Investigator. Insmed. Oct 2011 - May 2012.

A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis. Principal Investigator. Apr 2009 - Apr 2012.

Randomized, Active-Controlled Multicenter Study to assess the Efficacy, Safety and Tolerability of Repeated Cycles of Arikace® in Cystic Fibrosis with Chronic Infection Due to Pseudomonal aeruginosa. Principal Investigator. Oct 2011 - Mar 2012.

Cystic Fibrosis Translational Development Center
. Principal Investigator. Cystic Fibrosis Foundation. Jan 2010 - Dec 2012.